Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies

IF 7.6 1区医学 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet Regional Health: Western Pacific Pub Date : 2024-09-01 DOI:10.1016/j.lanwpc.2024.101183

Claire O'Callaghan , Johannes C. Michaelian , Yoko Aihara , Veeda Michelle Anlacan , Christopher Chen , Gary Cheung , Etuini Ma'u , Tuan Anh Nguyen , Ming-Chyi Pai , Anna Palagyi , Maw Pin Tan , Shyh Poh Teo , Yuda Turana , Huali Wang , Gloria Wong , Sharon L. Naismith

{"title":"Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies","authors":"Claire O'Callaghan , Johannes C. Michaelian , Yoko Aihara , Veeda Michelle Anlacan , Christopher Chen , Gary Cheung , Etuini Ma'u , Tuan Anh Nguyen , Ming-Chyi Pai , Anna Palagyi , Maw Pin Tan , Shyh Poh Teo , Yuda Turana , Huali Wang , Gloria Wong , Sharon L. Naismith","doi":"10.1016/j.lanwpc.2024.101183","DOIUrl":null,"url":null,"abstract":"<div><div>Here we first review the limited available literature addressing the current landscape of specialist assessment services for dementia and cognitive decline and the preparedness for new amyloid-targeting therapies for Alzheimer's disease across the Western Pacific region. Considering the scarcity of literature, as national representatives of Western Pacific nations we were then guided by the World Health Organization's Global Action Plan on Dementia to provide country-specific reviews. As a whole, we highlight that the existing diverse socioeconomic and cultural landscape across the region poses unique challenges, including varying access to services and marked differences among countries in their preparedness for upcoming amyloid-targeting therapies for Alzheimer's disease. Therefore, there is an urgent call for intergovernmental collaboration and investment across the Western Pacific to ensure that for all nations, citizens living with dementia and cognitive decline have access to effective and equitable methods of diagnosis, treatment and care.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Regional Health: Western Pacific","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666606524001779","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Here we first review the limited available literature addressing the current landscape of specialist assessment services for dementia and cognitive decline and the preparedness for new amyloid-targeting therapies for Alzheimer's disease across the Western Pacific region. Considering the scarcity of literature, as national representatives of Western Pacific nations we were then guided by the World Health Organization's Global Action Plan on Dementia to provide country-specific reviews. As a whole, we highlight that the existing diverse socioeconomic and cultural landscape across the region poses unique challenges, including varying access to services and marked differences among countries in their preparedness for upcoming amyloid-targeting therapies for Alzheimer's disease. Therefore, there is an urgent call for intergovernmental collaboration and investment across the Western Pacific to ensure that for all nations, citizens living with dementia and cognitive decline have access to effective and equitable methods of diagnosis, treatment and care.

查看原文本刊更多论文

西太平洋地区的痴呆症诊断和治疗服务：面对淀粉样蛋白靶向疗法的挑战、准备情况和机遇

在此，我们首先回顾了现有的有限文献，这些文献涉及目前西太平洋地区痴呆症和认知功能衰退的专家评估服务以及阿尔茨海默病淀粉样蛋白靶向新疗法的准备情况。考虑到文献资料的稀缺性，作为西太平洋国家的国家代表，我们在世界卫生组织《痴呆症全球行动计划》的指导下提供了针对具体国家的综述。总体而言，我们强调该地区现有的多样化社会经济和文化背景带来了独特的挑战，包括获得服务的途径各不相同，以及各国对即将推出的阿尔茨海默病淀粉样蛋白靶向疗法的准备程度存在明显差异。因此，迫切需要在整个西太平洋地区开展政府间合作和投资，以确保所有国家患有痴呆症和认知能力下降的公民都能获得有效和公平的诊断、治疗和护理方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Lancet Regional Health: Western Pacific Medicine-Pediatrics, Perinatology and Child Health

CiteScore

8.80

自引率

2.80%

发文量

305

审稿时长

11 weeks

期刊介绍： The Lancet Regional Health – Western Pacific, a gold open access journal, is an integral part of The Lancet's global initiative advocating for healthcare quality and access worldwide. It aims to advance clinical practice and health policy in the Western Pacific region, contributing to enhanced health outcomes. The journal publishes high-quality original research shedding light on clinical practice and health policy in the region. It also includes reviews, commentaries, and opinion pieces covering diverse regional health topics, such as infectious diseases, non-communicable diseases, child and adolescent health, maternal and reproductive health, aging health, mental health, the health workforce and systems, and health policy.